PENETRATION OF FOSCARNET INTO CEREBROSPINAL-FLUID OF AIDS PATIENTS

被引:35
作者
RAFFI, F [1 ]
TABURET, AM [1 ]
GHALEH, B [1 ]
HUART, A [1 ]
SINGLAS, E [1 ]
机构
[1] HOP UNIV BICETRE,F-94270 LE KREMLIN BICETR,FRANCE
关键词
D O I
10.1128/AAC.37.9.1777
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The diffusion of foscarnet into cerebrospinal fluid (CSF) was studied in 27 patients with AIDS. Foscarnet was administered intravenously at various dosages at 12-h intervals. Concentrations in plasma and CSF at the end of foscarnet infusion or 1, 3, 5, 6, and 12 h after infusion were determined by high-performance liquid chromatography. Thirty-seven samples were obtained. The median concentration of foscarnet in CSF was 80 mumol/liter (range, 0 to 500 mumol/liter). The CSF foscarnet concentration was greater than the 50% inhibitory concentration for human immunodeficiency virus type 1 and was equal to or greater than the 50% inhibitory concentration for cytomegalovirus in most cases. The penetration of foscarnet into CSF, as expressed by the ratio of the concentration in CSF to the simultaneous concentration in plasma, ranged from 0 to 3.4 (median, 0.27) and was highly correlated with the presence of cells within CSF and the length of foscarnet therapy. Good diffusion of foscarnet in CSF allows evaluation of this drug in central nervous system cytomegalovirus and human immunodeficiency virus infections in patients with AIDS.
引用
收藏
页码:1777 / 1780
页数:4
相关论文
共 15 条
[1]   COMPARATIVE ACTIVITY OF SELECTED ANTIVIRAL COMPOUNDS AGAINST CLINICAL ISOLATES OF HUMAN CYTOMEGALOVIRUS [J].
ANDREI, G ;
SNOECK, R ;
SCHOLS, D ;
GOUBAU, P ;
DESMYTER, J ;
DECLERCQ, E .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (12) :1026-1033
[2]   PHARMACOKINETICS OF CONCOMITANTLY ADMINISTERED FOSCARNET AND ZIDOVUDINE FOR TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (AIDS CLINICAL-TRIALS GROUP PROTOCOL-053) [J].
AWEEKA, FT ;
GAMBERTOGLIO, JG ;
VANDERHORST, C ;
RAASCH, R ;
JACOBSON, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1773-1778
[3]  
CHRISP P, 1991, DRUGS, V41, P102
[4]   COMBINATIONS OF 3'-AZIDO-3'-DEOXYTHYMIDINE (ZIDOVUDINE) AND PHOSPHONOFORMATE (FOSCARNET) AGAINST HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND CYTOMEGALO-VIRUS REPLICATION INVITRO [J].
ERIKSSON, BFH ;
SCHINAZI, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :663-669
[5]   INVIVO ADDITIVE ANTIRETROVIRAL EFFECT OF COMBINED ZIDOVUDINE AND FOSCARNET THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION (ACTG PROTOCOL 053) [J].
JACOBSON, MA ;
VANDERHORST, C ;
CAUSEY, DM ;
DEHLINGER, M ;
HAFNER, R ;
MILLS, J .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) :1219-1222
[6]   CLINICAL-PHARMACOLOGY - FOSCARNET [J].
LIETMAN, PS .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 :S8-S11
[7]   ANTIVIRAL EFFECTS OF PHOSPHONOFORMATE (PFA, FOSCARNET SODIUM) [J].
OBERG, B .
PHARMACOLOGY & THERAPEUTICS, 1989, 40 (02) :213-285
[8]   DETERMINATION OF PHOSPHONOFORMATE (FOSCARNET) IN BIOLOGICAL-FLUIDS BY ION-PAIR REVERSED-PHASE LIQUID-CHROMATOGRAPHY [J].
PETTERSSON, KJ ;
NORDGREN, T ;
WESTERLUND, D .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 488 (02) :447-455
[9]  
ROBERT C, 1991, ANAL DESCRIPTIVE MUL
[10]  
SANDSTROM EG, 1985, LANCET, V1, P1480